Today's Hours: 8:00am - 10:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    Elizabeth P. Rakoczy, editor.
    Summary: In this book, leading experts provide detailed descriptions of the exciting treatments that are expected to become part of the ophthalmologist?s arsenal within the next 10?20 years. The treatments discussed relate to a wide variety of conditions, including macular degeneration, Leber?s congenital amaurosis, retinitis pigmentosa and choroideremia. The authors explain clearly how different gene and cell therapies work and provide first-hand accounts of the difficulties that they have faced in bringing these technologies to clinical trial, such as issues relating to funding and ownership. Results achieved to date are presented, and the further steps required before the treatment in question can become a routine option are considered. Gene- and Cell-Based Treatment Strategies for the Eye is unique in showing the organic development of cutting-edge science into potential treatments for eye disease without compromising on accurate reporting of scientific facts. It will persuade the average practitioner or researcher ? whether ophthalmologist, health worker, or scientist ? that change is indeed coming and is not just a hollow promise of the tabloid media.

    Contents:
    Introduction
    Gene Therapy for Leber?s Congenital Amaurosis due to RPE65 Mutations
    Gene Therapy for Choroideremia
    Gene Therapy for Dominantly Inherited Retinal Degeneration
    Age-Related Macular Degeneration: The Challenges
    Neovascular Age Related Macular Degeneration: Secretion Gene Therapy
    Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium for the Treatment of Macular Degeneration
    Restoring Physiologic Barriers Against Neovascular Invasion.
    Digital Access Springer 2015
  • Article
    Fennell WH, Chua KG, Cohen L, Morgan J, Karunaratne HB, Resnekov L, Al-Sadir J, Lin CY, Lamberti JJ, Anagnostopoulos CE.
    J Thorac Cardiovasc Surg. 1979 Aug;78(2):244-53.
    One hundred consecutive patients undergoing aorta-coronary bypass grafting (ACBG) alone, without ventricular venting, were prospectively studied to determine the incidence and consequence of perioperative myocardial infarction (PMI) and the clinical variables that were predictive of PMI. Incidence was determined by serial electrocardiography (ECG) 100 patients; serum CK, GOT, and LDH (100 patients). CK isoenzymes (qualitative 100 patients, quantitated 50 patients); vectorcardiography (VCG) (78 patients); and 99mtechnetium pyrophosphate scintigraphy (TcPyp) (52 patients). The incidence of PMI by ECG was 9%; an additional 8% of cases was diagnosed by enzymes alone. The incidence of diagnostic change by VCG was 19% and by scintigraphy, 25%. Using at least one changed variable of the remaining three as the reference standard, the relative sensitivity and relative specificity of given variables in the diagnosis of PMI were as follows: ECG 67% and 100%, respectively; VCG 85% and 94%; scintigraphy 92% and 97%; and serum enzymes 86% and 96%. By univariate analysis, unstable angina was the only significant predictor of PMI. The operative mortality rate was 2% and the mortality rate at 12 months was 5%. There was a significantly greater mortality rate in patients with PMI diagnosed by ECG (p less than 0.01), in patients with unstable angina pectoris before operation (p less than 0.05), and in women (p less than 0.05).
    Digital Access Access Options